Congenital myasthenic syndromes: current diagnostic and therapeutic approaches
- PMID: 22911480
- DOI: 10.1055/s-0032-1323850
Congenital myasthenic syndromes: current diagnostic and therapeutic approaches
Abstract
Congenital myasthenic syndromes (CMS) are rare genetically and clinically heterogeneous disorders characterized by an impaired neuromuscular transmission. Exact prevalence data are not available, approximately 2000 to 3000 patients worldwide have been diagnosed on a molecular level; mutations in 14 different genes are known to date leading to causal defects in presynaptic nerve terminal, synaptic cleft, and postsynaptic apparatus. At last, all known mutations are estimated to cause approximately 50% of all clinically diagnosed CMS. However, phenotypes may vary widely and symptoms can be unspecific, therefore CMS are often missed and their prevalence may be underestimated. But, the exact diagnosis is extremely important to start early appropriate therapy to prevent life-threatening events and to improve the clinical course. Most patients are eligible for drug therapy with esterase inhibitors, 3, 4-diaminopyridine, ephedrine, fluoxetine or quinidine, but the effect of these drugs differs depending on the underlying genetic defect. Moreover, very little is known about the best treatment and care in these patients over a longer period of time.This article provides an overview of specific clinical symptoms, diagnostic work-up, and care including possible pharmacotherapy in case of CMS.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Similar articles
-
Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes.Brain. 2008 Mar;131(Pt 3):747-59. doi: 10.1093/brain/awm325. Epub 2008 Jan 7. Brain. 2008. PMID: 18180250
-
Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations.Neuromuscul Disord. 2012 Apr;22(4):318-24. doi: 10.1016/j.nmd.2011.09.002. Epub 2011 Nov 15. Neuromuscul Disord. 2012. PMID: 22088788
-
[Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy--The French National Congenital Myasthenic Syndrome Network experience].Rev Neurol (Paris). 2013 Feb;169 Suppl 1:S45-55. doi: 10.1016/S0035-3787(13)70060-2. Rev Neurol (Paris). 2013. PMID: 23452772 Review. French.
-
Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission.Expert Rev Mol Med. 2007 Aug 9;9(22):1-20. doi: 10.1017/S1462399407000427. Expert Rev Mol Med. 2007. PMID: 17686188 Review.
-
Congenital endplate acetylcholinesterase deficiency responsive to ephedrine.Neurology. 2005 Jul 12;65(1):144-6. doi: 10.1212/01.wnl.0000167132.35865.31. Neurology. 2005. PMID: 16009904
Cited by
-
Guideline for the management of myasthenic syndromes.Ther Adv Neurol Disord. 2023 Dec 26;16:17562864231213240. doi: 10.1177/17562864231213240. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 38152089 Free PMC article. Review.
-
Can Scoliosis Help the Early Diagnosis of Congenital Myasthenic Syndrome?Cureus. 2023 Sep 24;15(9):e45875. doi: 10.7759/cureus.45875. eCollection 2023 Sep. Cureus. 2023. PMID: 37766777 Free PMC article.
-
A case report of congenital myasthenic syndrome caused by a mutation in theCHRNE genein the Iranian population.Iran J Child Neurol. 2020 Fall;14(4):87-94. Iran J Child Neurol. 2020. PMID: 33193787 Free PMC article.
-
Congenital Myasthenic Syndromes or Inherited Disorders of Neuromuscular Transmission: Recent Discoveries and Open Questions.J Neuromuscul Dis. 2017;4(4):269-284. doi: 10.3233/JND-170257. J Neuromuscul Dis. 2017. PMID: 29125502 Free PMC article. Review.
-
Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome.J Neurosci. 2013 Jun 19;33(25):10559-67. doi: 10.1523/JNEUROSCI.4629-12.2013. J Neurosci. 2013. PMID: 23785168 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
